Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.

Cardiovascular research - 1 Oct 2016

Gui Yuzhou, Yao Sheng, Yan Hong, Hu Liang, Yu Chengyin, Gao Fei, Xi Cong, Li Huihui, Ye Yang, Wang Yiping

Abstract excerpt

AIMS: Atherosclerosis is the most common cause of cardiovascular diseases, such as myocardial infarction and stroke. We hypothesized that nagilactone B (NLB), a small molecule extracted from the root bark of Podocarpus nagi (Podocarpaceae), suppresses atherosclerosis in an atherosclerotic mouse model. METHODS AND RESULTS: Male apoE-deficient mice on C57BL/6J background received NLB (10 and 30 mg/kg) for 12 weeks....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver X Receptors
Share to Aortic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter 1

Share to ATP Binding Cassette Transporter, Subfamily G, Member 1

Share to Diterpenes

Share to Hypolipidemic Agents

Share to Plaque, Atherosclerotic

Share to RAW 264.7 Cells

Source

Identifiers

PMID: 27460841
DOI: 10.1093/cvr/cvw183

Genes

ABCA1
ABCG1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.PMID 27460841Read ↗

Liver X Receptors and their Agonists: Targeting for Cholesterol Homeostasis and Cardiovascular DiseasesSemantic proximity Read ↗

Beyond the Foam Cell: The Role of LXRs in Preventing AtherogenesisSemantic proximity Read ↗

Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease- associated pathology in a 3xTg-AD mouse modelSemantic proximity Read ↗

Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics.Semantic proximity Read ↗

G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE-/- mice.Semantic proximity Read ↗

MLN4924 inhibits macrophage foam cell formation by enhancing autophagy and regulating metabolic phenotype.Semantic proximity Read ↗

Astragalus flavone ameliorates atherosclerosis and hepatic steatosis via improving lipid metabolism and inhibition of inflammation in apoE-/- miceSemantic proximity Read ↗

The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against AtherogenesisSemantic proximity Read ↗

Isoginkgetin stabilizes atherosclerotic plaques by targeting NR4A2 to modulate the PPAR signaling pathway and reprogram ceramide metabolism, thereby inhibiting vascular smooth muscle cell phenotypic transformation.Semantic proximity Read ↗

Notoginsenoside R1 targets PPAR-γ to inhibit Hepatic Stellate Cell activation and ameliorates liver fibrosisSemantic proximity Read ↗

Artesunate inhibits macrophage-like phenotype switching of vascular smooth muscle cells and attenuates vascular inflammatory injury in atherosclerosis via NLRP3.Semantic proximity Read ↗

Resmetirom Attenuates Atherosclerosis in ApoE ⁻/⁻ Mice by Suppressing the NF- κB/ROS–NLRP3 Inflammasome AxisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.